() announced that the first UK subject has been treated at the Oxford Eye Hospital, part of Oxford University Hospitals NHS Foundation Trust, as part of the second stage of clinical trials.
The pharma company is evaluating its candidate for the treatment of retinitis pigmentosa (RP), an inherited, degenerative eye disease.
The remaining study participants are expected to be treated by the end of 2021, the AIM-listed firm said.
ReNeuron’s hRPC therapeutic candidate is undergoing Phase 2a clinical evaluations for the treatment of RP, which affects 1 in 4,000 people in the US and worldwide. The expanded study encompasses four sites worldwide, with two sites in the US as well as the recently activated sites in the UK and in Spain.
